Dynamic interplay between CXCL levels in chronic Hepatitis C patients treated by Interferon

Virology Journal

Volumn 10, Issue , 2013, Pages

  Zekri, Abdel Rahman N ^a   Bahnassy, Abeer A ^c   Mohamed, Waleed S ^a   Alam El Din, Hanaa M ^a   Shousha, Hend I ^b   Zayed, Naglaa ^b   Eldahshan, Dina H ^d   Abdel Aziz, Ashraf Omar ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c NATIONAL CANCER INSTITUTE   (Egypt)

^d BENI SUEF UNIVERSITY   (Egypt)

Author keywords

Chemokine's; E Cadherin; HCV; IFN

Indexed keywords

CHEMOKINE; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; CXCL16 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; STROMAL CELL DERIVED FACTOR 1; UVOMORULIN; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; CADHERINS; CHEMOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 84879496857     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-218     Document Type: Article

References (34)

1. Hepatitis C. Medscape. Mukherjee S, 2011 http://emedicine.medscape.com/ article/177792-overview
2. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I, Lancet 2000 355 9207 887 891 10.1016/S0140-6736(99)06527-7 10752705
3. El-Zanaty F, Way A, Egypt demographic and health survey 2008 Cairo, Egypt: Ministry of Health, El-Zanaty and Associates, and Macro International 2009 Available at http://www.measuredhs.com/pubs/pdf/FR220/FR220.pdf
4. Genetic epidemiology of hepatitis C virus throughtout Egypt. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL, J Infect Dis 2000 182 698 707 10.1086/315786 10950762
5. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group, Ann Intern Med 2004 140 346 355 10.7326/0003-4819-140-5-200403020-00010 14996676
6. Peginterferon alfa-2a (40kDa) and ribavirin: comparable rates of sustained virological response in Sub-sets of older and younger HCV genotype 1 patients. Reddy KR, Messinger D, Popescu M, Hadziyannis SJ, J Viral Hepat 2009 16 10 724 731 10.1111/j.1365-2893.2009.01122.x 19486469
7. Host factors and failure of interferon-a treatment in hepatitis C virus. Gao B, Hong F, Radaeva S, Hepatology 2004 39 880 890 10.1002/hep.20139 15057887
8. Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon? Lee SS, Abdo AA, J Antimicrob Chemother 2003 51 487 491 10.1093/jac/dkg135 12615848
9. Improving outcome in patients with hepatitis C virus genotype 4. Kamal S, Am J Gastroenterology 2007 102 2582 2588 10.1111/j.1572-0241.2007.01538.x
10. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, Castera L, De Ledinghen V, Marcellin P, Poupon R, Bourlière M, Zarski JP, Roudot-Thoraval F, Observational VHC4 Study Group, J Viral Hepatitis 2007 14 460 467 10.1111/j.1365-2893.2006.00823.x
11. Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4. Zekri AR, Haleem HA, Esmat GE-D, Bahnassy AA, El-Din HMA, Hafez MM MM, Sharaby AF, Sharaf H, Zakaria MSE-D, J Viral Hepatitis 2007 14 468 477 10.1111/j.1365-2893.2006.00832.x
12. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, Rekacewicz C, Gad RR, Vignier N, Abdel-Hamid M, Zalata K, Bedossa P, Pol S, Fontanet A, Mohamed MK, J Med Virol 2009 81 1576 1583 10.1002/jmv.21570 19626613
13. Cytokine profile in Egyptian HCV genotype-4 in relation to liver disease progression. Zekri AR, Ashour MS, Hassan A, Alam El-Din HM, El-Shehaby AM, Abu-Shady MA, World J Gastroenterol 2005 11 42 6624 6630 16425355
14. Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics. Wald O, Weiss ID, Galun E, Peled A, Cytokine 2007 39 50 62 10.1016/j.cyto.2007.05.013 17629707
15. Association of pretreatment serum interferon c inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy ingenotype 1 infected patients with chronic hepatitis C. Diago M, Castellano G, García-Samaniego J, Pérez C, Fernández I, Romero M, Iacono OL, García-Monzón C, Gut 2006 55 374 379 10.1136/gut.2005.074062 16150856
16. Evidence for an antagonistform of the chemokine CXCL10 in patients chronically infected with HCV. Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, Vallet-Pichard A, Mallet V, Mottez E, Mapes J, Fontanet A, Pol S, Albert ML, J Clin Invest 2011 121 1 308 317 10.1172/JCI40594 21183794
17. Soluble inflammatory markers as predictors of virological response in patients with chronic hepatitis C virus infection treated with interferon-α plus ribavirin. Moura AS, Carmo RA, Teixeira AL, Teixeira MM, Rocha MO, Memorias do Instituto Oswaldo Cruz 2011 106 1 38 43 10.1590/S0074-02762011000100006 21340353
18. The role of chemokines as inflammatory Mediators in Chronic Hepatitis C Virus Infection. Zeremski M, Petrovic LM, Talal AH, J Viral Hepat 2007 14 10 675 687 17875002
19. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Rot A, Von Andrian UH, Annu Rev Immunol 2004 22 891 928 10.1146/annurev.immunol.22.012703.104543 15032599
20. Th1 and Th2 cytokines are elevated in HCV-infected SVR(+) patients treated with interferon-a. Wan L, Kung YJ, Lin YJ, Liao CC, Sheu JJ, Tsai Y, Lai HC, Peng CY, Tsai FJ, Biochemical and Biophysical Research Communications 2009 379 855 860 10.1016/j.bbrc.2008.12.114 19118522
21. Gene expression profiles on three kinds of genotype hepatitis C virus core protein in Huh-7 cell line with microarray analysis. Dou J, Wang J, Liu PB, Zhang XJ, Zhonghua Yu Fang Yi Xue Za Zhi 2006 40 1 38 41 16620599
22. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, Di Bisceglie AM, Charles ED, Talal AH, Jacobson IM, Rice CM, Dustin LB, Blood 2005 106 1175 1182 10.1182/blood-2005-01-0126 15860662
23. CXCR3 expression on peripheral CD4+ T cells as a predictive marker of response to treatment in chronic hepatitis C. Perney P, Turriere C, Portalès P, Rigole H, Psomas C, Blanc F, Clot J, Corbeau P, Clin. Immunol 2009 132 1 55 62 10.1016/j.clim.2009.03.521 19423402
24. Altered chemotactic response of myeloid and plasmacytoid dendritic cells from patients with chronic hepatitis C: role of alpha interferon. Cicinnati VR, Kang J, Sotiropoulos GC, Hilgard P, Frilling A, Broelsch CE, Gerken G, Beckebaum S, Journal of General Virology 2008 89 1243 1253 10.1099/vir.0.83517-0 18420803
25. Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vacuities. Sansonno D, Tucci FA, Troiani L, Lauletta G, Montrone M, Conteduca V, Sansonno L, Dammacco F, Blood 2008 112 5 1620 1627 10.1182/blood-2008-02-137455 18550853
26. Pretreatment expression of the perforin gene by circulating CD8(+) T lymphocytes predicts biochemical response to interferon-alpha in patients with chronic hepatitis C. Balian A, Naveau S, Zou W, Durand-Gasselin I, Bouchet L, Foussat A, Galanaud P, Chaput JC, Emilie D, Eur. Cytokine Netw 2000 11 177 184 10903796
27. Interferons alpha and beta as immune regulators-a new look. Biron CA, Immunity 2001 14 661 664 10.1016/S1074-7613(01)00154-6 11420036
28. Cell adhesion system and human cancer morphogenesis. Hirohashi S, Kanai Y, Cancer Sci 2005 94 575 581
29. Hepatitis C virus core protein downregulates E- cadherin expression via activation of DNA methyltransferase 1 and 3b. Arora P, Kim E, Jung J, Jank KL, Cancer Letters 2008 261 244 252 10.1016/j.canlet.2007.11.033 18164808
30. Management of hepatitis C. National Institutes of Health Consensus Development Conference Statement, Hepatology 2002 36 supp1 3 S20 http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm 12407572
31. Consensus siRNA for inhibition of HCV genotype-4 replication. Zekri AR, Bahnassy AA, Alam El-Din HM, Salama HM, Virology J 2009 6 13 10.1186/1743-422X-6-13
32. TRUGENE sequencing versus INNO-LiPA for sub-genotyping of HCV genotype-4. Zekri AR, El-Din HM, Bahnassy AA, El-Shehabi AM, El-Leethy H, Omar A, Khaled HM, J Med Virol 2005 75 3 412 420 10.1002/jmv.20293 15648068
33. Formulation and application of numerical scaring system for assessing histological activity in asymptomatic chronic active hepatitis. Knodell RG, Ishak KG, Black WC, Hepatology 1981 1 431 435 10.1002/hep.1840010511 7308988
34. Classification of chronic hepatitis: diagnosis, grading and staging. Desmet VJ, Gerber M, Hoofnagle JH, Hepatology 1994 19 1513 1520 10.1002/hep.1840190629 8188183